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Abstract: In chronic lymphocytic leukemia, the hypoxia-inducible factor 1 (HIF-1) regulates the response
of tumour cells to hypoxia and their protective interactions with the leukemic microenvironment. In this
study we demonstrate that chronic lymphocytic leukemia cells from TP53-disrupted (TP53dis) patients
have constitutively higher expression levels of the ฀-subunit of HIF-1 (HIF-1 ฀) and increased HIF-1 tran-
scriptional activity, compared to the wild type counterpart. In the TP53dis subset, HIF-1 ฀ upregulation
is due to reduced expression of the HIF-1 ฀ ubiquitin ligase von Hippel-Lindau protein (pVHL). Hypoxia
and stromal cells further enhance HIF-1฀ accumulation, independently from the TP53 status. Hypoxia
acts through the downmodulation of pVHL and the activation of the PI3K/AKT and RAS/ERK1-2
pathways, whereas stromal cells induce an increased activity of the RAS/ERK1-2, RHOA/RHOA kinase
and PI3K/AKT pathways, without affecting pVHL expression. Interestingly, we observed that higher
levels of HIF-1A mRNA correlate with a lower susceptibility of leukemic cells to spontaneous apoptosis,
and associate with the fludarabine resistance that mainly characterizes TP53dis tumour cells. The HIF-
1฀ inhibitor BAY87-2243 exerts cytotoxic effects toward leukemic cells, regardless of the TP53 status,
and has anti-tumour activity in E฀-TCL1 mice. BAY87-2243 also overcomes the constitutive fludarabine
resistance of TP53dis leukemic cells and elicits a strongly synergistic cytotoxic effect in combination with
ibrutinib, thus providing preclinical evidences for its further investigation as a potential new drug in
chronic lymphocytic leukemia.
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n chronic lymphocytic leukemia (CLL), the hypoxia-inducible factor 1
(HIF-1) regulates the response of tumor cells to hypoxia and their pro-
tective interactions with the leukemic microenvironment. In this
study, we demonstrate that CLL cells from TP53-disrupted (TP53dis)
patients have constitutively higher expression levels of the α-subunit of
HIF-1 (HIF-1α) and increased HIF-1 transcriptional activity compared to
the wild-type counterpart. In the TP53dis subset, HIF-1α upregulation is
due to reduced expression of the HIF-1α ubiquitin ligase von Hippel-
Lindau protein (pVHL). Hypoxia and stromal cells further enhance 
HIF-1α accumulation, independently of TP53 status. Hypoxia acts
through the downmodulation of pVHL and the activation of the
PI3K/AKT and RAS/ERK1-2 pathways, whereas stromal cells induce an
increased activity of the RAS/ERK1-2, RHOA/RHOA kinase and
PI3K/AKT pathways, without affecting pVHL expression. Interestingly,
we observed that higher levels of HIF-1A mRNA correlate with a lower
susceptibility of leukemic cells to spontaneous apoptosis, and associate
with the fludarabine resistance that mainly characterizes TP53dis tumor
cells. The HIF-1α inhibitor BAY87-2243 exerts cytotoxic effects toward
leukemic cells, regardless of the TP53 status, and has anti-tumor activity
in Eµ-TCL1 mice. BAY87-2243 also overcomes the constitutive fludara-
bine resistance of TP53dis leukemic cells and elicits a strongly synergistic
cytotoxic effect in combination with ibrutinib, thus providing preclinical
evidence to stimulate further investigation into use as a potential new
drug in CLL.
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ABSTRACT
Introduction
Chronic lymphocytic leukemia (CLL) patients with
high-risk genomic features such as disruption of the TP53
gene [i.e. del(17p) and TP53 mutations] respond poorly to
chemoimmunotherapy and frequently relapse.1-9
Significant advances have been made in the treatment of
CLL following  the introduction of Bruton tyrosine kinase
(BTK) inhibitors.10 Ibrutinib, which is currently approved
for the front-line treatment of CLL, induces long-lasting
responses in the majority of patients, improving outcome
with relatively limited toxicities.10 However, patients with
disruption of the TP53 gene (TP53dis) treated with ibrutinib
are still characterized by a poorer outcome.11
Hypoxia inducible factor 1 (HIF-1) is an essential regula-
tor of cell adaptation to hypoxia and is often up-regulated
in tumors due to intratumoral hypoxia or activation of
oncogenic pathways.12,13 In tumors, HIF-1 fosters different
tumor-promoting mechanisms, including metabolic adap-
tation, neoangiogenesis, cell survival and invasion.14 
HIF-1 is a heterodimer, which consists of a constitutive-
ly expressed HIF-1β subunit and an inducible HIF-1α sub-
unit. Besides its traditional regulation via proteasomal
degradation, other signaling pathways, such as PI3K/AKT
and RAS/ERK1-2, contribute to HIF-1α accumulation, via
stability regulation or synthesis induction.12,15 
HIF-1α is constitutively expressed in CLL cells com-
pared to normal B cells due to microRNA-mediated down-
regulation of the von Hippel-Lindau protein (pVHL),16 a
ubiquitin ligase responsible for HIF-1α degradation.12 In
addition, in CLL cells, HIF-1α is up-regulated by interac-
tions with stromal cells (SC) and by exposure to hypoxic
microenvironments, thus promoting the survival and
propagation of leukemic cells, and their metabolic adapta-
tion to the protective conditions of the tumor niche.17-20
We have already reported that HIF-1α is involved in drug
resistance mechanisms in patients with unmutated (UM)
immunoglobulin heavy chain variable region genes
(IGHV).20 The TP53 gene encodes one of the best-studied
tumor suppressor proteins, which is often mutated in can-
cer, thus promoting cell survival, proliferation and drug
resistance.21 p53 may also play a pivotal role in the regula-
tion of HIF-1α, since in conditions of prolonged
hypoxia/anoxia, the protein accumulates and promotes
HIF-1α destruction.22 In solid tumors, loss of TP53 func-
tion associates with constitutive elevated levels of 
HIF-1α.12,22,23
In this study, we found that HIF-1α is over-expressed in
CLL cells from patients carrying TP53 aberrations, also
elucidating the molecular mechanisms implicated in the
constitutive (TP53-related) and inducible (hypoxia- and
SC-induced) HIF-1α upregulation. In addition, we
observed that the HIF-1α inhibitor BAY87-2243 exerts
potent anti-tumor functions, overcoming the constitutive
fludarabine resistance of TP53-disrupted CLL cells, and




A total of 102 patients with CLL, diagnosed according to the
International Workshop on CLL-National Cancer Institute
guidelines,24 were included in the study [40 TP53dis and 62 TP53-
wild type (TP53wt) cases] (Online Supplementary Table S1).
Healthy donors’ (HD, n=2) samples were provided by the local
blood bank. Patients were untreated or off-therapy for at least 12
months before sampling of peripheral blood (PB) for the experi-
ments. Samples were collected after patients’ informed consent
in accordance with the Declaration of Helsinki and after
approval by the local Institutional Review Board. PB mononu-
clear cells (PBMC) were isolated and characterized as detailed in
the Online Supplementary Appendix.
Cell lines
The Burkitt’s lymphoma cell line, Séraphine, and the mantle
cell lymphoma cell line, Granta-519, were kindly provided by T.
Zenz. The TP53wt and the CRISPR/Cas9-mediated TP53 knock-
out version (TP53ko) of Granta-519 and Séraphine cell lines were
used in the study. The M2-10B4 murine SC line (ATCC #CRL-
1972) was also used. Cell lines were maintained as reported in
the Online Supplementary Appendix.
Animals
C57BL/6 Eµ-TCL1 mice were maintained in specific pathogen-
free animal facilities and treated in accordance with European
Union and Institutional Animal Care and Use Committee (number
716) guidelines. Splenic cells (5x106) were injected intraperitoneally
into syngeneic C57BL/6 mice, and experiments were performed
with groups of 4-6 mice. Leukemic mice were treated when tumor
cells reached 10% in PB. BAY87-2243 was administered at 
4 mg/kg in ethanol/solutol/water solution once daily by oral gav-
age. Mice were sacrificed at the end of treatment.
Cell culture 
In selected experiments, CLL cells were cultured in the pres-
ence or absence of M2-10B4 SC, and exposed to PD98059
(Sigma Aldrich, Milan), Y27632 (Sigma Aldrich) or LY249002
(Sellekchem, Houston, TX, USA) for 48 hours (h). CLL cells were
exposed for 48 h to BAY87-2243 (Sellekchem); 2-Fluoroadenine-
9-β-D-arabinofuranoside (F-ara-A, Sigma Aldrich); ibrutinib
(Sellekchem) used alone or in combination, at the indicated con-
centrations. Culture conditions were normoxia or mild hypoxia
(1% O2), 5% CO2 at 37°C. 
Western blot
Full details can be found in the Online Supplementary Appendix
together with the list of antibodies used for western blot (WB)
analyses.
Quantitative real-time polymerase chain reaction  
Full details of quantitative real-time polymerase chain reac-
tion (qRT-PCR) experiments can be found in the Online
Supplementary Appendix together with the list of primer
sequences.
Gene set enrichment analysis 
Gene set enrichment analysis (GSEA, http://www.broad.mit.
edu/gsea/index.jsp) was performed as previously described.25,26
Gene sets were assessed as significantly enriched in one of the
phenotypes if the nominal P-value and the false discovery rate
(FDR)-q value were <0.05.
RHOA and RAS, ERK1-2, AKT and RHOA kinase activity
The isoprenylated membrane-associated RAS or RHOA pro-
teins and the non-isoprenylated cytosolic forms were detected
as previously described.20 Details of  measurement of ERK1-2,
AKT and RHOA kinase activity are reported in the Online
Supplementary Appendix.
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Cell viability assay
Cell viability was evaluated by flow cytometry using Annexin-
V/Propidium Iodide (Ann-V/PI) staining with the MEBCYTO-
Apoptosis Kit (MBL Medical and Biological Laboratories, Naka-ku
Nagoya). 
Statistical analysis
GraphPad Prism (version 6.01, San Diego, CA, USA) was used
to perform paired and unpaired t-test, and to calculate Pearson cor-
relation coefficient. Results are expressed as mean±standard error
of mean (SEM), unless otherwise specified. Statistical significance
was defined as a P<0.05. Combination analysis was performed
using Compusyn software; combinations were considered syner-
gistic when the combination index (CI) was <1.
Results
HIF-1α is over-expressed in chronic lymphocytic
leukemia cells from TP53dis patients and in TP53
knockout lymphoma cell lines 
Expression levels of HIF-1α protein were comparatively
evaluated in HD CD19+ cells, and in CLL cells isolated
from TP53dis and TP53wt samples. As expected, HD CD19+
B cells did not express HIF-1α at the baseline normoxic
conditions (data not shown). In contrast, leukemic cells
from CLL patients exhibited detectable cytosolic and
nuclear HIF-1α protein (Figure 1A). Interestingly, CLL cells
from patients carrying TP53 abnormalities (TP53dis CLL
cells) had significantly higher amounts of the cytosolic and
nuclear fractions of HIF-1α subunit, as well as higher 
HIF-1AmRNA levels compared to CLL cells isolated from
TP53wt cases (TP53wt CLL cells) (Figure 1A and B). We eval-
uated an enlarged cohort of cases and observed that the
association between the expression of HIF-1α and the
TP53 status was not influenced by the IGHV mutational
status (Online Supplementary Figure S1). The transcriptional
activity of HIF-1α was evaluated through the expression
of selected target genes.13,15,27 We found a higher expression
of GLUT1 and ENO1 in TP53dis CLL cells, compared to
TP53wt samples (Figure 1C and D). To corroborate the
finding of an association between HIF-1α expression and
TP53 status we exploited cell line models. Interestingly,
the expression of HIF-1α protein and mRNA was higher in
TP53ko Granta-519 and Séraphine lymphoma cell lines,
compared to the p53wt (Figure 1E and F). In line with this
finding, expression of  VEGF, GLUT1 and ENO1 was also
significantly higher in TP53ko than in TP53wt Granta-519
and Séraphine cell lines (Figure 1G). 
To further investigate the link between TP53 and 
HIF-1α, we performed GSEA on previously published
microarray data from tumor cells isolated from seven
TP53dis and 13 TP53wt cases (geocode GSE18971).28 Data of
GSEA cases revealed that the TP53 abnormalities were
associated with an upregulation of a number of genes
belonging to the
“GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP” gene
set (Figure 2A). The protein ELK3 participates in the tran-
scriptional response to hypoxia and controls the expres-
sion of several regulators of HIF-1α stability.29
Consistently, the baseline expression of ELK3 was higher
in TP53dis compared to TP53wt CLL cells (Figure 2B). 
Given its role in HIF-1α regulation,12,30 we also compared
pVHL expression in TP53dis and TP53wt samples. Notably,
CLL cells from TP53dis patients had reduced amounts of
pVHL compared to TP53wt patients, most likely being
responsible for better stabilization of the HIF-1α protein
and a repression of its proteasomal degradation in TP53dis
cells (Figure 2C). As for HIF-1α expression, there were no
differences between pVHL levels according to IGHV
mutational status (Online Supplementary Figure S2). These
data suggest that TP53 abnormalities lead to a reduced
expression of pVHL and subsequently to an accumulation
of HIF-1α protein. 
Hypoxia and stromal cells further increase HIF-1α
expression in chronic lymphocytic leukemia cells from
TP53dis and TP53wt patients
We next investigated whether microenvironmental sig-
nals, such as oxygen deprivation12 and the interactions
with SC,20 had differential effects on HIF-1α according to
the TP53 status of the leukemic cells, also in an attempt to
better define the underlying molecular mechanisms. To
this end, CLL cells were cultured for 48 h in condition of
hypoxia or in the presence of SC. Of note, ex vivo culture
partially abrogated the TP53-related differential expres-
sion of HIF-1α observed at the baseline in freshly isolated
CLL cells. In hypoxia, we observed a marked upregulation
of the cytosolic and nuclear fractions of HIF-1α protein,
which was independent of TP53 status (Figure 3A), and
was associated to a reduced expression of pVHL (Figure
3B), and to an activation of the PI3K/AKT and RAS/ERK1-
2 pathways (Figure 3C-F). Consistently, we observed that
blocking concentration of pharmacologic agents inhibiting
ERK1-2 (PD98059) and PI3K (LY294002) effectively coun-
teracted the hypoxia-induced HIF-1α upregulation, inde-
pendently of TP53 status (Figure 3G). 
In line with previous data,20 we observed a marked
upregulation of the cytosolic and nuclear amounts of the
HIF-1α when CLL cells were co-cultured with SC (Figure
4A). SC-induced HIF-1α elevation was not associated to a
reduced pVHL expression in leukemic cells (Figure 4B),
whereas we observed an increased activation of
RHOA/RHOA kinase (Figure 4C and D), PI3K/AKT
(Figure 4E), and RAS/ERK1-2 (Figure 4F) signaling path-
ways. As confirmation, we found that targeted inhibition
of ERK1-2, PI3K and RHOA kinase by blocking concentra-
tions of pharmacologic agents (i.e. PD98059, LY294002
and Y27632, respectively) effectively counteracted SC-
induced HIF-1α upregulation (Figure 4G). 
The role of these pathways in modulating HIF-1α over-
expression was corroborated by titration experiments
showing that exposure of TP53dis and TP53wt CLL cells to
increasing concentrations of PD98059, LY294002 and
Y27632 induced a progressive reduction of the activity of
the targeted kinases, which was associated to a dose-
dependent decrease in HIF-1α levels (Online Supplementary
Figure S3). 
The selective HIF-1α inhibitor BAY87-2243 has 
anti-tumor activities in  chronic lymphocytic leukemia
In line with the role of HIF-1α as a promoting factor for
cell survival,12we found a positive correlation between the
baseline levels of HIF-1A mRNA and the 48-h viability of
CLL cells during in vitro culture (Figure 5A). Consistently,
the viability of leukemic cells isolated from samples char-
acterized by baseline HIF-1A mRNA levels above the
median value of the entire cohort (HIF-1Ahigh) was signifi-
cantly higher than the viability of CLL cells displaying
lower HIF-1A values (HIF-1Alow) (Figure 5B and Online
V. Griggio et al.
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Supplementary Figure S4). Based on these observations, and
on previous data reporting HIF-1α as a potential therapeu-
tic target in CLL,17 we evaluated the anti-tumor effect of
BAY87-2243, a selective inhibitor of HIF-1α. First, we
observed that BAY87-2243 effectively inhibited HIF-1α
protein expression at the cytosolic and nuclear level, both
in TP53dis and TP53wt CLL cells (Figure 5C), also counter-
acting the HIF-1α upregulation exerted by hypoxia and SC
(Figure 5D and E). After 48 h, BAY87-2243 determined a
strong cytotoxic effect toward leukemic cells isolated from
both patient subsets (Figure 5F and Online Supplementary
Figure S5). Of note, the downregulation of HIF-1α was
also evident at 24-h exposure, when cell viability was still
well preserved, thus confirming that it was determined by
a targeted inhibitory effect rather than by a consequence
of cell death (data not shown). BAY87-2243 exerted a cyto-
HIF-1α in TP53-disrupted CLL cells
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Figure 1. HIF-1α is over-expressed and more active in primary cells isolated from patients with chronic lymphocytic leukemia (CLL) and in lymphoma cell lines car-
rying a TP53 disruption. The expression of HIF-1α and HIF-1α target genes was measured in TP53dis and TP53wt CLL cells and in lymphoma TP53wt and TP53ko cell
lines. (A) Western blot (WB) analysis for HIF-1α protein expression in freshly isolated TP53dis and TP53wt CLL cells. A representative blot is shown with relative Unique
Patient Numbers (UPN) and cumulative band intensity data obtained from the analysis of 17 TP53wt and 15 TP53dis CLL patients. Box plots represent median value
and 25-75% percentiles, whiskers represent minimum and maximum values of band intensity for each group. (B-D) Real-time-polymerase chain reaction (RT-PCR)
analysis of HIF-1A, and its target genes GLUT1 and ENO1 expression levels in TP53dis and TP53wt CLL cells. (E) WB analysis for HIF-1α protein expression in the TP53wt
and TP53ko Granta-519 and Séraphine cell lines. Representative blot of three independent experiments is shown. (F) RT-PCR analysis of HIF-1A in the TP53wt and
TP53ko Granta-519 and Séraphine cell lines. (G) RT-PCR analysis of VEGF, GLUT1 and ENO1 in the TP53wt and TP53ko Granta-519 and Séraphine cell lines showed a
significantly higher expression level of all analyzed genes in TP53ko samples.(B, C and D) Box and whiskers plots represent median values and 25-75% percentiles;
whiskers represent minimum and maximum values for each group. (F and G) Bar graphs represent mean results obtained from three experiments together with stan-




toxic effect also when TP53dis and TP53wt CLL cells were
cultured for 48 h in the presence of extrinsic signals induc-
ing a further upregulation of baseline levels of HIF-1α,
such as hypoxia (Figure 5G and Online Supplementary
Figure S6) and co-culture with SC (Figure 5H and Online
Supplementary Figure S7). 
To further corroborate these data and the ability of
BAY87-2243 to exert effective anti-tumor functions in
CLL, we used a murine model derived from the transfer of
Eµ-TCL1 leukemic cells into syngeneic mice.17 In line with
the results reported by Valsecchi et al.,17 showing that 
HIF-1α regulates the interaction of CLL cells with the
bone marrow (BM) microenvironment, we observed that
BAY87-2243 significantly reduced BM infiltration by
leukemic cells, also inducing cytotoxicity in a consistent
proportion of CLL cells (Figure 5I-K). The anti-tumor
effect observed with BAY87-2243 in the BM was not evi-
dent in the PB and spleen compartments (data not shown),
suggesting that, in a murine model of aggressive and rap-
idly growing CLL, HIF-1αmay serve as a pro-survival fac-
tor, especially for the leukemia reservoir residing in the
BM.
In conclusion, our data indicate that HIF-1α is a pro-sur-
vival factor in CLL, which can be effectively targeted by
the pharmacologic agent BAY87-2243, a specific inhibitor
with potent anti-tumor effects both in vitro and in vivo.
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Figure 2. TP53dis chronic lymphocytic leukemia (CLL)  cells show an upregulation of several genes involved in response to hypoxia and express reduced levels of
von Hippel-Lindau protein (pVHL). (A) Gene set enrichment analysis (GSEA) on CLL cells from TP53dis and TP53wt patients. The plot of the Enrichment Score (ES) versus
the gene list index and a portion of the corresponding heatmap highlighting the relative expression of gene members belonging to the
“GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP” gene set are depicted. 54 out of 126 genes from the gene set were significantly up-regulated in the TP53dis cohort of
patients compared to the TP53wt cohort. (B) Western blot (WB) for ELK3 baseline expression in TP53dis and TP53wt CLL cells. A representative blot is shown with rel-
ative Unique Patient Numbers (UPN) and cumulative band intensity data obtained from the analysis of 9 TP53wt and 6 TP53dis CLL patients. (C) WB for pVHL baseline
expression in TP53dis and TP53wt CLL cells. A representative blot is shown with relative UPN and cumulative band intensity data obtained from the analysis of 15
TP53wt and 12 TP53dis CLL patients. Box plots represent median value and 25-75% percentiles; whiskers represent minimum and maximum values of band intensity
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Figure 3. Hypoxia further increases HIF-1α expression in TP53dis and TP53wt chronic lymphocytic leukemia (CLL) cells via the PI3K/AKT and RAS/ERK1-2 signaling
pathways. Primary CLL cells were cultured for 48 hours under normoxic and hypoxic conditions. (A and  B) Western blot (WB) analyses detected a higher amount of
cytosolic and nuclear HIF-1α and lower amount of von Hippel-Lindau protein (pVHL) in TP53dis and TP53wt CLL cells cultured in hypoxia (H) compared to normoxia (N).
(C and  D) Immuno-enzymatic measurement showed that RHOA-GTP and RHOA kinase activities were unaffected by hypoxia. (E and  F) WB analyses for AKT, RAS and
ERK1-2. TP53dis and TP53wt CLL cells had higher expression of the active form of AKT [p(Ser 473)AKT],  RAS (RAS-GTP) and ERK1-2 [p(Thr202/Tyr204,
Thr185/Tyr187]ERK1-2) in hypoxia compared to normoxia. (G) WB analyses for HIF-1α. The targeting of ERK1-2 with 10 µM PD98059 (PD) and of PI3K with 10 µM
LY294002 (LY) reduced HIF-1α expression in CLL cells, both in hypoxia and normoxia, and independently from the TP53 status. (A) Results  from two representative
cases of seven TP53wt patients and two representative cases of five  TP53dis patients. Representative blots are shown with relative Unique Patient Numbers (UPN)
and cumulative band intensity data. Box plots represent median values and 25-75% percentiles; whiskers represent minimum and maximum values of band intensity
for each group. (B, E and F) Results  from one representative experiment in four TP53wt patients and one representative experiment in three TP53dis patients. Bar
graphs represent mean values together with standard error of mean. (C and D) Multiple line graphs represent individual data values for the same sample in each
condition. (G) Results from one representative experiment in three TP53wt patients and one representative experiment in three TP53dis patients. Vertical lines have
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Figure 4. Stromal cells (SC) increase HIF-1α expression in TP53dis and TP53wt chronic lymphocytic leukemia (CLL) cells via PI3K/AKT, RAS/ERK1-2 and
RHOA/RHOA kinase signaling pathways. Primary CLL cells were cultured for 48 hours in the presence and in the absence of M2-10B4 SC. (A and  B) Western blot
(WB) analyses for HIF-1α and von Hippel-Lindau protein (pVHL). SC up-regulated the cytosolic and nuclear expression of HIF-1α but did not affect pVHL expression
in TP53dis and TP53wt CLL cells. (C and D) Immuno-enzymatic measurement showed that the co-culture with SC increased RHOA-GTP and RHOA kinase activities in
TP53dis and TP53wt CLL cells. (E and  F) WB analyses for AKT, RAS and ERK1-2. Higher amount of the active form of AKT [p(Ser 473)AKT], RAS (RAS-GTP) and ERK1-
2 [p(Thr202/Tyr204, Thr185/Tyr187)ERK1-2] were detectable in both TP53wt and TP53dis CLL cells cultured with SC. (G) WB analyses for HIF-1α. The targeting of
ERK1-2 with 10 µM PD98059 (PD), of RHOA kinase with 10 µM Y27632 (Y276), and of PI3K with 10 µM LY294002 (LY) reduced HIF-1α expression in CLL cells,
both in the presence and in the absence of SC, regardless of the TP53 status. (A) Results from two representative cases of  ten  TP53wt patients and two represen-
tative cases of four TP53dis patients. Representative blots are shown, together with Unique Patient Numbers (UPN)  and cumulative band intensity data. Box plots
represent median values and 25-75% percentiles; whiskers represent minimum and maximum values of band intensity for each group. (B and G) Results are from
one representative experiment in three TP53wt patients and one representative experiment in three TP53dis patients. (C and D) Multiple line graphs represent indi-
vidual data values for the same sample in each condition. (E and F) Results are from one representative experiment in five TP53wt patients and one representative
experiment in four TP53dis patients. Bar graphs represent mean values together with standard error of mean. Vertical lines have been inserted to indicate reposi-
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Figure 5. HIF-1α promotes chronic lymphocytic leukemia (CLL) cell survival and its inhibition exerts a direct cytotoxicity, also in the presence of HIF-1α inducing
microenvironmental stimuli. (A) Correlation of HIF-1A gene expression and 48-hour (h) cell viability of CLL cells as determined by Annexin V/propidium iodide assay.
(B) The median value of HIF-1A mRNA expression of a cohort of 25 CLL samples was selected as the cut-off to identify HIF-1Ahigh and HIF-1Alow CLL cells. HIF-1Ahigh
showed significantly higher 48-h cell viability compared to HIF-1Alow CLL cells. (C) Western blot (WB) analyses for HIF-1α. The exposure to 1 µM BAY87-2243 (BAY)
for 48 h reduced the cytosolic and nuclear amount of HIF-1α in CLL cells isolated from both TP53wt and TP53dis patient subsets. A representative blot is shown, togeth-
er with Unique Patient Numbers (UPN) and cumulative band intensity data obtained from the analysis of 14 TP53wt and 4 TP53dis CLL patients. Box plots represent
median value and 25-75% percentiles; whiskers represent minimum and maximum values of band intensity for each group. (D and E) Primary CLL cells were exposed
to 1 µM BAY for 48 h under normoxic and hypoxic conditions, in the absence and in the presence of M2-10B4 stromal cells (SC), and evaluated for HIF-1α expression
by WB. BAY87-2243 was able to lower HIF-1α expression in CLL cultured in normoxic and hypoxic conditions, and in the absence or in the presence of SC, independ-
ently of TP53 status. (F-H) Cell viability of TP53dis and TP53wt CLL cells exposed for 48 h to 1 µM BAY87-2243, under normoxia and hypoxia, or in co-culture with SC.
The treatment with BAY87-2243 determined a significant decrease in the viability of TP53wt and TP53dis CLL cells, compared to untreated controls, both in normoxia
and hypoxia. After exposure to SC, BAY87-2243 significantly reduced the viability of TP53dis and TP53wt CLL cells, not completely overcoming the SC protective effect.
In blot representations, vertical lines have been inserted to indicate repositioned gel lanes. (I) Scheme of the in vivo experiment with mice transplanted with the
EµTCL1-derived leukemia. (J) Percentage of leukemic cells (CD19+) in the bone marrow (BM) of mice transplanted with the Eµ-TCL1-derived leukemia, treated with
BAY87-2243, and euthanized as in (I). (K) Percentage of AnnV+ leukemic cells (CD19+) in the BM of mice transplanted with Eµ-TCL1-derived leukemia, treated with
BAY87-4432, and euthanized as in (I). (A) Data are represented by a scatter plot. (J and K) Data are represented as bee-swarm plots. (B) Box and whiskers plots rep-
resent median values and 25-75% percentiles; whiskers represent minimum and maximum values for each group. (D) Results are from one representative experi-
ment in three TP53wt patients and one representative experiment in three TP53dis patients. (E) Results are from one representative experiment in seven TP53wt
patients and one representative experiment in four TP53dis patients. (F, G and H) Box and whiskers plots represent median values and 25-75% percentiles; whiskers






BAY87-2243 restores fludarabine sensitivity of TP53dis
chronic lymphocytic leukemia  cells and counteracts
the protective effect of stromal cells  
We next examined whether BAY87-2243 was also effec-
tive in overcoming the intrinsic resistance to fludarabine
of CLL cells from TP53dis patients.9,31-33 As expected, in our
cohort, the normalized cell viability after 48-h F-ara-A
treatment was significantly higher in TP53dis compared to
TP53wt CLL cells (Figure 6A). Consistently, we observed
that CLL cells with a normalized cell viability ≥0.5, arbi-
trarily considered as fludarabine-resistant, were mostly
TP53dis and had a significantly higher baseline expression
of HIF-1A mRNA compared to fludarabine-sensitive cells
(i.e. normalized cell viability <0.5) (Figure 6B).
Interestingly, BAY87-2243 enhanced the cytotoxicity of
fludarabine on TP53dis CLL cells, as shown by the signifi-
cant impairment of cell viability observed after combined
treatment with BAY87-2243 + fludarabine compared to
each compound used as a single agent (Figure 6C). The
cytotoxic effect exerted by the combination was strongly
V. Griggio et al.
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Figure 6. HIF-1AmRNA is over-expressed in fludarabine-resistant chronic lymphocytic leukemia (CLL) cells and HIF-1α inhibition is capable of restoring fludarabine
sensitivity. (A) Normalized cell viability (i.e. the ratio between the percentage of AnnV/PI negative CLL cells cultured in the presence of F-ara-A and the percentage
of AnnV/PI negative CLL cells left untreated) of TP53dis and TP53wt CLL cells exposed for 48 hours (h) to 10 µM F-ara-A. (B) A normalized cell viability of 0.5 was
selected as the cut-off value to identify fludarabine-resistant (i.e. normalized cell viability ≥0.5) and fludarabine-sensitive (i.e. normalized cell viability <0.5) CLL cells.
Fludarabine-resistant CLL cells showed significantly higher baseline levels of HIF-1A mRNA compared to fludarabine-sensitive. Eight of 10 (80%) fludarabine-resis-
tant samples derived from TP53dis patients, and 13 of 14 (93%) fludarabine-sensitive samples derived from TP53wt patients. (C) Normalized cell viability of TP53dis
and TP53wt CLL cells exposed for 48 h to 1 µM BAY87-2243 (BAY) and/or 10 µM F-ara-A. The combination BAY87-2243 + F-ara-A (striped pattern) determined a sig-
nificant decrease in the viability of TP53wt and TP53dis CLL cells, compared to each compound used as single agent and to untreated controls. (D) Heatmaps showing
normalized viability after 48-h treatment with BAY87-2243 + fludarabine as single agents or in combination, used at different concentrations. Asterisks indicate the
combinations which determined a significant reduction in cell viability compared to each single agent, at the corresponding concentration. (A and C) Box plots 
represent median values and 25-75% percentiles; whiskers represent minimum and maximum values for each group, together with all points. (B) Data are repre-




synergistic (CI=0.17) on TP53disCLL cells and was also evi-
dent, although less remarkable, on TP53wtCLL cells (Figure
6C and Online Supplementary Figure S8). Interestingly, we
observed that combinations consisting of lower concen-
trations of BAY87-2243 + fludarabine were capable of
inducing significant reductions in cell viability compared
to each drug used as a single agent, and this effect was par-
ticularly evident in the TP53dis CLL subset (Figure 6D). The
cytotoxic activity of the combinations was also strongly
synergistic, as shown by data on CI (Online Supplementary
Figure S9). Notably, the significantly higher cytotoxicity of
the combination BAY87-2243 + fludarabine was main-
tained even when both TP53dis and TP53wt CLL cells were
cultured under hypoxia (Online Supplementary Figure S10A
and B) or in the presence of SC (Online Supplementary
Figure S10C and D). 
These results indicate that BAY87-2243 and fludarabine
synergistically eliminate primary CLL cells, and that their
effect is maintained even in the presence of HIF-1α induc-
ing factors that recapitulate the BM niche microenviron-
ment.
The combination of BAY87-2243 and ibrutinib exerts a
synergistic cytotoxic effect on chronic lymphocytic
leukemia cells
Previously reported data indicate that TP53-mutated
CLL cells have a lower sensitivity to ibrutinib cytotoxicity
in vitro34 and that ibrutinib-induced apoptosis is significant-
ly reduced in conditions of hypoxia.19 Therefore, we
hypothesized that the combination of an HIF-1α inhibitor
and ibrutinib may represent a potentially attractive next
step for patients carrying TP53 abnormalities, who are
characterized by constitutively higher levels of HIF-1α.
Our results show that the combination of BAY87-2243 +
ibrutinib determined a significant impairment in the via-
bility of TP53dis and TP53wt CLL cells compared to each
compound used as a single agent, and was very strongly
synergistic (Figure 7A and Online Supplementary Figure
S11). Interestingly, similar effects were observed also with
lower concentrations of both agents (Figure 7B and Online
Supplementary Figure S12). Notably, the combination
BAY87-2243 + ibrutinib exerted a significantly higher
cytotoxic effect compared to each single compound even
when CLL cells from both TP53dis and TP53wt samples
were cultured in the presence of SC (Figure 7C).
Overall, these data demonstrate that BAY87-2243 exerts
a compelling synergistic effect with ibrutinib, thus provid-
ing the rationale for future clinical translation.
Discussion
In this study, we investigated the expression and regula-
tion of HIF-1α in TP53dis CLL cells and its potential role as
a therapeutic target. We found that CLL cells carrying
TP53 abnormalities express significantly higher baseline
levels of HIF-1α and have increased HIF-1α transcriptional
activity compared to TP53wt cells. Regardless of  TP53 sta-
tus, the resting levels of HIF-1α are susceptible to further
upregulation by microenvironmental stimuli, such as
hypoxia and SC. Our data show that HIF-1α is a suitable
therapeutic target, the inhibition of which induces a
strong cytotoxic effect, capable also of reversing the in vitro
fludarabine resistance of TP53dis CLL cells and of exerting
synergistic effects with ibrutinib.
Hypoxia has a detrimental role in the pathobiology of
several solid and hematologic tumors.35,36 The identifica-
tion of new potential targets in CLL is certainly important
for high-risk patients, for whom there is still no effective
cure, and, in addition, the development of new therapies
might be effective in a broader setting of B-cell lympho-
proliferative disorders.
It has been previously reported that HIF-1α levels vary
considerably among CLL patients and that its overexpres-
sion is a predictor of a poor survival.17,37 In line with obser-
vations made in solid tumors, where p53 promotes the
ubiquitination and proteasomal degradation of the HIF-1α
subunit in hypoxia,12,22we postulated that abnormalities of
the TP53 gene might have an influence on the regulation
of HIF-1α in CLL cells. To the best of our knowledge, this
is the first study examining the differential expression and
transcriptional activity of HIF-1α in patients with 
TP53-deficient CLL, also uncovering new mechanisms for
HIF-1α modulation in leukemic cells. Our data show that
the high-resting levels of HIF-1α detected in TP53dis sam-
ples associate both to an increased transcription, as shown
by the higher HIF-1A mRNA levels, and to a decreased
degradation, as shown by the higher baseline expression
of ELK3 and by the lower pVHL amounts. 
We next investigated the cellular pathways implicated
in HIF-1α regulation mediated by extrinsic factors.
Hypoxia-induced HIF-1α upregulation is not only due to a
reduced pVHL-mediated protein degradation, which is a
well-known mechanism in condition of oxygen depriva-
tion, but also to an increased activation of RAS/ERK1-2
and PI3K/AKT signaling pathways. In contrast, pVHL
expression in leukemic cells is not affected by SC, which
instead activate the RAS/ERK1-2, RHOA/RHOA kinase
and PI3K/AKT intracellular pathways, thus leading to HIF-
1α overexpression. These results endorse recent data that
implicate a number of paracrine factors in the transcrip-
tional and translational regulation of HIF-1α in different
tumor models.38 
Previous data have suggested that HIF-1α targeting is a
promising therapeutic strategy in CLL, potentially capable
of synergizing with chemotherapeutic agents. The only
HIF-1α inhibitor that has been preclinically tested in CLL
is EZN-2208, a topoisomerase I inhibitor that has also
been shown to down-modulate HIF-1α.17 We therefore
tested BAY87-2243, a more selective HIF-1α inhibitor that
has already shown in vivo anti-tumor efficacy in a lung
tumor model, without any signs of toxicity.39 Interestingly,
BAY87-2243 demonstrated a direct cytotoxicity towards
leukemic cells isolated from CLL patients, and this effect
was independent of TP53 status. As far as we know, this
is the first evidence of the anti-tumor activity of BAY87-
2243 in hematologic tumors, and particularly in CLL.
Patients with CLL and TP53 abnormalities are intrinsi-
cally resistant to fludarabine-based chemotherapy regi-
mens.9,31-33,40,41 Our data demonstrate: i) higher baseline lev-
els of HIF-1α in fludarabine-resistant CLL cells; and ii) a
further upregulation of HIF-1α after exposure to hypoxia
and SC. Given this, we investigated the ability of BAY87-
2243 to overcome both intrinsic (i.e. TP53-related) and
inducible (i.e. SC-induced) resistance to fludarabine. Our
data show that BAY87-2243 potently synergizes with flu-
darabine in vitro, and that their combined cytotoxic effect
was especially evident in TP53dis samples. Interestingly,
HIF-1α inhibition was also effective in overcoming the
TP53-independent fludarabine-resistance induced by
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extrinsic factors recapitulating the BM microenvironment. 
Since HIF-1α critically regulates the interactions of CLL
cells with the BM stroma,17 the cytotoxic effects exerted
by BAY87-2243 in culture systems mimicking the tumor
niche could, in part, be the result of a perturbation of
molecular circuits triggered by microenvironmental stim-
uli that are implicated in cell survival and drug resistance.
Data showing that hypoxia and SC induce HIF-1α overex-
pression support the hypothesis that, within the tumor
niche, leukemic cells become highly dependent on its pro-
survival effect. In line with this assumption, we found that
treatment with BAY87-2243 induced a marked reduction
in leukemic infiltration and a parallel increase in the pro-
portion of apoptotic leukemic cells in the BM of a CLL
transplantable model derived from the Eµ-TCL1 trans-
genic mice. Of note, the inhibition of HIF-1α may have
beneficial effects also on the non-leukemic milieu. Recent
data have shown that infiltration by CLL cells into BM
could result in tissue-site hypoxia, causing: i) increased
expression of HIF-1α in hematopoietic progenitors, which
V. Griggio et al.
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Figure 7. BAY87-2243 plus ibrutinib combinations exerts synergistic cytotoxic effects and is effective in impairing chronic lymphocytic leukemia (CLL)  cell viability
in the presence of stromal cells (SC). (A) Normalized 48-hour (h) viability of TP53dis and TP53wt CLL cells exposed to 1 µM BAY87-2243 (BAY) and 10 µM ibrutinib,
used as single agents or in combination (striped pattern). Box plots represent median value and 25-75% percentiles; whiskers represent minimum and maximum
values for each group, together with all points. (B) Heatmaps showing normalized viability after 48-h treatment with BAY87-2243 + ibrutinib as single agents or in
combination, used at different concentrations. Asterisks indicate the combinations which determined a significant reduction in cell viability compared to each single
agent, at the corresponding concentration. (C) Normalized 48-h viability of TP53dis and TP53wt CLL cells exposed to 1 µM BAY87-2243 and 10 µM ibrutinib, used as
single agents or in combination (striped pattern), in co-culture with M2-10B4 SC. Box plots represent median value and 25-75% percentiles; whiskers represent min-




leads to an impaired hematopoiesis and a reduced output
of innate immune cells into the blood; and ii) impaired
functions of different immune cell subsets.19,42 Overall, this
evidence endorses the concept of HIF-1α inhibition as a
very promising therapeutic strategy in CLL.
In the era of new targeted treatments, ibrutinib has
determined a dramatic change in the therapeutic land-
scape and has become the standard of care for the major-
ity of CLL patients.43-45 However: i) ibrutinib is not suitable
for all CLL patients and may have limited availability in
several countries; ii) complete responses are infrequent,
and indefinite drug administration is usually needed to
maintain a clinical response; and iii) the development of
ibrutinib resistance in CLL cells has been demonstrated.46,47
Even more importantly, TP53dis CLL patients show a sub-
optimal long-term response to ibrutinib,48 and 
TP53-mutated CLL cells have a lower sensitivity to ibruti-
nib cytotoxicity in vitro.34 Since our data show that TP53dis
samples are characterized by higher levels and function of
HIF-1α (which is a crucial target to overcome the constitu-
tive and inducible drug resistance of CLL cells), we
hypothesized that the combination of BAY87-2243 and
ibrutinib might be an attractive approach for in vitro test-
ing. We found that dual targeting of HIF-1α alongside BTK
function produces a synergistic cytotoxic activity towards
primary CLL cells, also in the presence of TP53 abnormal-
ities; thus suggesting the possibility of improving ibrutinib
efficacy through this novel therapeutic association. 
Overall, our data indicate that HIF-1α is over-expressed
in CLL cells, especially in the presence of TP53 aberra-
tions, and that it is susceptible to further upregulation
through microenvironmental stimuli. From the transla-
tional standpoint, the pharmacologic compound BAY87-
2243, a selective inhibitor of HIF-1α, displays potent anti-
tumor properties and warrants further pre-clinical evalua-
tion in this disease setting, also in combination with other
therapies. Indeed, on one hand, the synergism of BAY87-
2243 and fludarabine may provide the rationale for future
clinical application in countries with limited access to
ibrutinib, particularly for the treatment of high-risk
patients carrying TP53 abnormalities. On the other hand,
BAY87-2243 coupled with ibrutinib may offer a rational
combination to increase the proportion of minimal resid-
ual disease negative remissions, thus reducing the devel-
opment of CLL clones with resistant mutations. 
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